All 11 Agenda Items Approved at Regular Shareholders’ Meeting
Five New Directors Appointed; New Committees Established
Expanding Authorized Shares Assigned as Task for New Board

At its first regular general meeting of shareholders since resolving its conflict with the Minority Shareholders Alliance, Oscotec appointed five new directors and passed all 11 agenda items as originally proposed. However, both inside and outside the voting hall, suspicions regarding the influence of the second-largest shareholder and calls to increase the number of authorized shares continued, revealing that the undercurrent of conflict remains unresolved.


Sanghyun Lee, CEO of Oscotec, is speaking at the "28th Regular Shareholders' Meeting" held on the 30th at Korea Bio Park in Seongnam-si, Gyeonggi Province. Photo by Minjae Kwak

Sanghyun Lee, CEO of Oscotec, is speaking at the "28th Regular Shareholders' Meeting" held on the 30th at Korea Bio Park in Seongnam-si, Gyeonggi Province. Photo by Minjae Kwak

View original image

Oscotec held its 28th Annual General Meeting of Shareholders on March 30 at Korea Bio Park in Seongnam, Gyeonggi Province. The central item on the agenda was the election of five directors through a cumulative voting system. The proposals included the appointment of in-house directors from the company’s management, such as CEO Taeyoung Yoon and Executive Director Dongjun Shin, as well as the appointment of Jinhyung Kang, Professor of Oncology at Seoul St. Mary’s Hospital, recommended by the Minority Shareholders Alliance, and outside directors Attorneys Kyusik Kim and Kyungseop Lee. All proposals were approved. With these appointments, the Oscotec board of directors expanded from four members to seven.


Previously, the two sides had clashed over the composition of the board but reached a compromise before the general meeting. The candidates Jinhyung Kang and Kyungseop Lee, who had initially been nominated by shareholders, were officially proposed by the company, and a revised disclosure was issued to confirm the election of five directors as a single agenda item through cumulative voting, thus bringing the dispute to a temporary close.


Suspicions of "Lee Giyoon’s Influence"... Pointed Questions Continue After Compromise


Although the agenda items were passed, the atmosphere at the meeting remained tense. Before the vote, one shareholder requested to speak and raised concerns about the influence of Lee Giyoon, Chairman of GK Asset and the second-largest shareholder. The shareholder stated, "According to public disclosures, shareholder Lee Giyoon holds a 9.9% stake, but there are suspicions among shareholders that, including borrowed-name accounts, his actual stake is about 18%." The shareholder further argued, "There are concerns that Kang Jinhyung’s candidacy was influenced by Chairman Lee." The shareholder added, "Although Chairman Lee does not officially participate in management, there have been reports that, at the previous general meeting and other formal occasions, he has undermined CEO Taeyoung Yoon’s expertise or pressured him to resign. This leads to suspicions that he may be exerting significant unofficial influence."


The company responded, "It is not appropriate for the company to directly address these suspicions," and added, "We do not represent the position of any particular shareholder. The board of directors makes decisions for the value of all shareholders and the company as a whole, based on a comprehensive review of various shareholder opinions."


Professor Jinhyung Kang addressed the matter directly after his appointment. He said, "It is true that I was recommended by the head of the Minority Shareholders Alliance, and that I met Chairman Lee Giyoon, but there was no collusion, request, or agreement during that meeting." He continued, "Regardless of who recommends a director, once appointed, it is our duty to work for the interests of all shareholders. This situation has made me reflect on the depth of mutual distrust. To promote healing, I will strive to deliver tangible results within one year."


Expanding Authorized Shares: The New Board’s First Task


Another shareholder at the meeting called on the new board to actively consider increasing the number of authorized shares to attract strategic investors (SI). The shareholder also asked directly whether opposition from shareholder Lee Giyoon and the Minority Shareholders Alliance was the reason the expansion of authorized shares had not progressed so far. The proposal to expand authorized shares was already voted down at the extraordinary general meeting in December 2025. At that time, Oscotec had sought to increase the number of authorized shares from 40 million to 50 million to raise capital from SIs or financial investors (FIs), with the goal of making its subsidiary Genosco a wholly owned subsidiary. CEO Sanghyun Lee responded, "The expansion of authorized shares and the attraction of strategic investors have been pursued from the beginning. The newly composed board will work to persuade opposing shareholders and push forward in a unified direction."


At this general meeting, a provision was also newly established to allow for the creation of board committees such as the Internal Transaction Committee, Investment Review Committee, and Outside Director Nomination Committee. The specific details on the composition, authority, and operation of each committee will be determined by board resolution. CEO Lee explained, "This is aimed at systematizing internal controls, risk management, and audit functions, and at increasing the fairness and transparency of major decisions." In particular, for major issues related to Genosco, the company plans to form a special committee centered on outside directors and external experts to enhance objectivity and transparency. In addition, other proposals, including revisions to the title of outside directors following amendments to the Commercial Act, the appointment of a standing auditor, approval of the limit on directors' compensation, and approval of the limit on auditors' compensation, were all passed as originally proposed.



Meanwhile, Oscotec’s consolidated sales for the previous year were 99,838,660,000 won, up 193.5% from the previous year. Operating profit turned positive at 52,083,290,000 won. CEO Lee stated, "We will reinvest these results in next-generation new drug development and make enhancing shareholder value our highest priority." Including online voting prior to the meeting, a total of 505 shareholders participated, representing 51.4% of shares with voting rights.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing